Exagen (XGN) Invested Capital (2018 - 2026)

Exagen has reported Invested Capital for 9 years, with the latest figure at $37.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 42.36% year-over-year to $37.3 million; the trailing twelve-month figure through Mar 2026 stood at $37.3 million (up 42.36% YoY), and the FY2025 full-year result was $39.1 million, up 36.69% from the prior year.
• Invested Capital for Q1 2026 stood at $37.3 million, down from $39.1 million in the prior quarter.
• The five-year high for Invested Capital was $103.8 million in Q1 2022, with the low at $26.2 million in Q1 2025.
• Historically, Invested Capital has averaged $51.8 million across 5 years, with a median of $41.4 million in 2023.
• Annual changes were most pronounced in 2023 — Invested Capital tumbled 44.23% — and 2026, when it surged 42.36%.
• Exagen's Invested Capital stood at $70.8 million in 2022, then slumped by 41.5% to $41.4 million in 2023, then sank by 30.81% to $28.6 million in 2024, then jumped by 36.69% to $39.1 million in 2025, then decreased by 4.72% to $37.3 million in 2026.
• The last three Invested Capital figures came in at $37.3 million (Q1 2026), $39.1 million (Q4 2025), and $41.1 million (Q3 2025), per Business Quant data.